Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00215904
Status:
COMPLETED
Last Update Posted:
2012-07-09
First Post:
2005-09-18
Brief Title:
D-serine Adjuvant Treatment for Parkinsons Disease
Sponsor:
Herzog Hospital
Organization:
Herzog Hospital
Study Overview
Official Title:
D-serine Adjuvant Treatment for Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The proposed experiment will evaluate the effects of the NMDA receptor full agonist D-serine 2gday on persistent symptoms of Parkinsons Disease and on antiparkinsonian drugs-induced dyskinesias
D-serine will be used as add-on therapy to on-going medications received by Parkinsons Disease patients The rational for this study stems from observations made in pervious clinical trials with schizophrenia patients in which it was demonstrated that D-serine adjuvant treatment resulted in1improvement of parkinsonian side effects induced by antipsychotic drugs and 2 improvement of depression and negative ie apathy blunted effects anhedonia symptoms which are similar to symptoms encountered in Parkinsons Disease
The study will have a crossover design in accordance to which each patient will receive in random order D-serine and placebo for a 6 weeks period each Thus any participant will have the opportunity to receive the experimental treatment
D-serine will be used as add-on therapy to on-going medications received by Parkinsons Disease patients The rational for this study stems from observations made in pervious clinical trials with schizophrenia patients in which it was demonstrated that D-serine adjuvant treatment resulted in1improvement of parkinsonian side effects induced by antipsychotic drugs and 2 improvement of depression and negative ie apathy blunted effects anhedonia symptoms which are similar to symptoms encountered in Parkinsons Disease
The study will have a crossover design in accordance to which each patient will receive in random order D-serine and placebo for a 6 weeks period each Thus any participant will have the opportunity to receive the experimental treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 20030312 | None | None | None |